Approval of Biocon, Mylan insulin product could herald cheaper insulin in U.S.

FDA decision is a blow for Sanofi, which markets blockbuster Lantus

After traveling a winding path that included patent disputes and complete response letters, Semglee insulin glargine from Biocon and Mylan has at last gained FDA’s approval to treat diabetes.

Biocon Ltd. (NSE:BIOCON; BSE:532523) and Mylan N.V. (NASDAQ:MYL)

Read the full 363 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers